Medical Industry News Archive

Click here to search our archive

Print using browser

URGENT MEDICINE RECALL: SANDOZ CEFPODOXIME 40mg/5ml Reg No A39/20.1.1/0397 (50ml and 100ml pack sizes)
Sandoz SA (Pty) Ltd in collaboration with the Medicines Control Council are initiating a Class 2, Type B recall on all batches of Sandoz Cefpodoxime 40mg /5ml (50ml and 100ml pack sizes).

Sandoz Cefpodoxime 40mg/5ml powder for oral suspension is an antibiotic used for short- term treatment of lower and upper respiratory tract infections in infants, children and adults.

The product is being recalled due to lower than expected efficacy, high unknown impurities, discolouration and formation of brownish agglomerates on certain batches of Sandoz Cefpodoxime 40mg/5ml tested during stability monitoring.

Use of the product may lead to weakened patient therapy through insufficient anti-infective treatment resulting in: a patient being contagious to others for a longer time, the development and spread of resistant bacterial strains, and significant therapeutic difficulties in eradication of respective bacteria.

In the interest of patient safety, Sandoz SA (Pty) Ltd request that you immediately return all batches of Sandoz Cefpodoxime 40mg/5ml stock without delay to your supplying wholesaler or distributor for full credit.
Sandoz SA (Pty) Ltd would like to thank you for your co-operation and apologise for any inconvenience caused.

Should you have any enquiries in this regard kindly contact the Sandoz Customer Call Centre 0861 SANCAL or 0861 726 225 during office hours and a technical support 24 hour call no 0768114744.

For full prescribing information please refer to package insert approved by Medical Regulatory Authority

Sandoz SA (Pty) Ltd PO Box 154, Isando 1600 Kempton Park, Gauteng South Africa Tel Fax +27 (0) 11 394 3084    Reg No: 1990/001979/07
Directors: R-A Bassoul (Canadian) J-C Dubos (French) M.M Paleja (Singaporean)  
A Novartis Company

You need to be logged in to see more details. Register Now!

Click here for more information .....
Contact: Carla Urbani-Smith, (Responsible Pharmacist)
Telephone: +27 (0) 11 929 9000
Date: Tuesday, February 14, 2012

Archive News Headlines
Aspen - Stock shortage - Flixonase Aqueous Nasal Spray (fluticasone propionate)
Pfizer - Stock Shortage - Valoron 50mg/ 5ml Drops 10ml (tilidine hydrochloride semi-hydrate)
MEDA Pharma add Optilast Eye Drops (azelastine) to their portfolio
Aspen - Stock Outage - Lamictin 200 mg tablets (lamotrigine)
Aspen - Stock Availability - Tertroxin 20 µg tablets (Liothyronine sodium (T3)
Pharma Dynamics launch Dyna Sertraline 50mg and 100mg Tablets
Zentiva launch Ziabeta tablets (bisoprolol fumarate, hydrochlorothiazide)
Novartis – Stock Outage of Ritalin LA 10mg capsules (methylphenidate hydrochloride)
Aspen launch Edurant tablets (rilpivirine 25mg)
Takeda - Stock Shortage - Theoplus 200mg tablets (theophylline, anhydrous)
Novartis – Stock Availability of Vibrocil (dimethindene maleate, phenylephrine and Neomycin sulphate) & Vibrocil-S (dimethindene maleate, phenylephrine) nasal sprays
Adcock discontinue Teargel (Carbomer)
AstraZeneca Pharmaceuticals launch Brilinta Tablets (ticagrelor 90 mg)
MEDA Pharma add Rhinolast Nasal Spray to portfolio (azelastine)
MEDA Pharma add Chamiflor Ocean Nasal Spray to their portfolio (physiological ocean water, chamomile fluid extract)
Adcock - Stock Outage - Scopex Co 10mg 500’s Tablets (hyoscine-N-butylbromide and dipyrone)
Aurobindo Pharma launch Hidrist 24mg tablets (betahistine dihydrochloride 24 mg)
Actavis Pharma - New Pack Sizes - Arrow Simvastatin 10 MG, 20 MG and 40 MG tablets
MSD - Stock Availability - Pregnyl 5000 IU and 1500 IU ampoules (chorionic gonadotrophin)
Pfizer discontinue Neurontin 800 mg tablets (gabapentin)